Benchmark upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.
Separately, Cantor Fitzgerald upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th.
Read Our Latest Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- Manufacturing Stocks Investing
- 5 Reasons the S&P 500 Could Rebound Strongly in 2025
- Investing in the High PE Growth Stocks
- Best Gold Stocks in 2025… So Far
- CD Calculator: Certificate of Deposit Calculator
- 5 Reasons Why Halliburton is a Good Buy in 2025
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
